TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options Under Clinical Evaluation
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Recurrent or Refractory Childhood CML
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Source links and citations
The following are examples of national and/or institutional clinical trials that are currently being conducted:
NCT04925479 (Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia): This study aims to determine the dose and safety profile of asciminib in pediatric patients who were previously treated with one or more TKIs.
Source links and citations
NCT03934372 (An Open-Label, Single-Arm, Phase I/II Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas, or Solid Tumors in Pediatric Participants): This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 year to younger than 18 years.
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Preserved source evidence · Not medical advice